Open: 21.92 Close: 21.31 Change: -0.61

Today's Summary

Sarepta Therapeutics announces refinancing of approximately $700 million of 1.25% convertible senior notes due 2027. Sareptas entered into exchange agreements with a limited number of holders of its Convertible Senior Notes due 20 27 that will extend maturity to 2030 while also de-levering the balance sheet. Sarepta Therapeutics is on an urgent mission to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. Sarepta Therapeutics shares were up 38.08% at $25.38 in after-hours trading at the time of publication Wednesday. The company introduced a strategic restructuring plan after the market close on Wednesday.